- Home
- WERN vs SVRA Comparison
WERN vs SVRA Comparison
Compare WERN & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WERN | SVRA |
|---|---|---|
| Founded | 1956 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | WERN | SVRA |
|---|---|---|
| Price | $29.95 | $6.82 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 13 | 8 |
| Target Price | ★ $26.23 | $6.88 |
| AVG Volume (30 Days) | 918.8K | ★ 3.1M |
| Earning Date | 10-30-2025 | 11-12-2025 |
| Dividend Yield | ★ 1.87% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.41 | N/A |
| Revenue | ★ $2,991,440,000.00 | N/A |
| Revenue This Year | $1.18 | N/A |
| Revenue Next Year | $4.50 | N/A |
| P/E Ratio | $72.57 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $23.02 | $1.89 |
| 52 Week High | $40.16 | $6.98 |
Technical Indicators
Market Signals| Indicator | WERN | SVRA |
|---|---|---|
| Relative Strength Index (RSI) | 70.94 | 79.68 |
| Support Level | $25.20 | $5.55 |
| Resistance Level | $30.26 | $6.78 |
| Average True Range (ATR) | 1.05 | 0.45 |
| MACD | 0.59 | 0.11 |
| Stochastic Oscillator | 95.83 | 90.79 |
Price Performance
Historical ComparisonAbout WERN Werner Enterprises Inc.
Werner Enterprises Inc is a transportation and logistics company. The company has two reportable segments - Truckload Transportation Services and Werner Logistics. It derives majority of its revenue from full-truckload transportation services and geographically from United States.
About SVRA Savara Inc.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.